• Gap26 Connexin 43 Mimetic Peptide: 3D Osteocyte Network Modu

  2026-04-30

  Explore how Gap26, a connexin 43 mimetic peptide, enables precise modulation of intercellular signaling in advanced 3D osteocyte network models. This article uniquely integrates cutting-edge mechanotransduction research with actionable protocols for calcium signaling and ATP release inhibition.

• N3-kethoxal: Precision RNA Structure Probing & DNA Mapping

  2026-04-30

  N3-kethoxal empowers researchers to map RNA secondary structures and accessible genomic DNA regions with unmatched specificity using bioorthogonal click chemistry. Its membrane-permeable, azide-functionalized design unlocks advanced workflows for in vitro and in vivo nucleic acid research, streamlining probe-labeling and interaction studies.

• CircCramp1l/miR-532-3p/HMGB1/Drp1 Axis Drives Allergic Rhini

  2026-04-29

  This study identifies a novel regulatory pathway in allergic rhinitis involving circCramp1l acting as a ceRNA for miR-532-3p, which modulates HMGB1 and Drp1-driven mitochondrial dysfunction. The findings highlight new molecular targets for AR intervention and clarify how mitochondrial dynamics intersect with immune responses.

• CYR61-Migrasome Axis Drives Osteogenic Recovery in Irradiate

  2026-04-29

  This study identifies the extracellular matrix protein CYR61, delivered via migrasomes, as a key regulator of migration and osteogenic differentiation in irradiation-damaged bone marrow mesenchymal stem cells (BMSCs). By elucidating the molecular and cellular mechanisms involved, these findings inform potential regenerative strategies for osteoradionecrosis of the jaw.

• CK2 and ERK8 Inhibition: Transforming Protein Phase Separati

  2026-04-28

  This thought-leadership article explores the strategic application of the CK2 and ERK8 inhibitor, a potent 2-(4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)acetic acid derivative, in advancing translational protein phase separation studies. Integrating recent findings on SARS-CoV-2 nucleocapsid LLPS and kinase signaling, we provide mechanistic guidance and actionable recommendations for researchers aiming to leverage this next-generation molecular tool.

• TPPU: Soluble Epoxide Hydrolase Inhibitor in Pain & Bone Mod

  2026-04-28

  TPPU empowers researchers to precisely manipulate fatty acid epoxide signaling in inflammatory pain and bone metabolism studies. Its nanomolar potency, robust oral bioavailability, and proven translational value make it a gold-standard tool for dissecting the sEH–Nrf2 axis in both acute and chronic disease models.

• Applied Uses of 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazol

  2026-04-27

  5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) delivers precise, reproducible control over transcriptional elongation, empowering advanced studies of cell fate, HIV transcription, and antiviral response. This article translates the latest mechanistic discoveries and validated protocols into actionable workflows and troubleshooting strategies that maximize the impact of DRB, as supplied by APExBIO, for cutting-edge research.

• Revisiting AMPK’s Role in Autophagy: Suppression via ULK1 In

  2026-04-27

  This study challenges the established paradigm by demonstrating that AMPK activation suppresses, rather than promotes, ULK1-mediated autophagy induction during energy stress. These insights fundamentally reshape our understanding of cellular adaptation to glucose starvation and have methodological implications for autophagy inhibition research.

• Dual CDK4/6 and BET Inhibition Suppresses Pancreatic EMT and

  2026-04-26

  Gu et al. (2025) demonstrate that combined inhibition of CDK4/6 and BET proteins synergistically suppresses pancreatic ductal adenocarcinoma (PDAC) growth and reverses epithelial-to-mesenchymal transition (EMT) by modulating the GSK3β-mediated Wnt/β-catenin pathway. Their work clarifies the paradoxical effects of CDK4/6 inhibition and highlights the therapeutic promise of dual-targeting strategies in PDAC.

• HRP Rabbit Anti-Goat IgG (H+L) Antibody: Precision in Immuno

  2026-04-25

  The HRP Rabbit Anti-Goat IgG (H+L) Antibody delivers high specificity and sensitivity for detecting goat primary antibodies across ELISA, western blot, and immunohistochemistry. Its robust HRP-conjugation and affinity purification make it a cornerstone reagent for studies requiring signal amplification and minimal background, including those investigating pulmonary toxicity mechanisms.

• hiPSC-Derived Intestinal Organoids for Pharmacokinetic Model

  2026-04-24

  This study introduces a streamlined protocol for generating human induced pluripotent stem cell (hiPSC)-derived intestinal organoids (IOs) with mature enterocyte features suitable for pharmacokinetic studies. The findings highlight improved model fidelity and practical scalability for evaluating drug absorption and metabolism in vitro.

• Plerixafor (AMD3100): Quantified Benchmarks in CXCR4 Inhibit

  2026-04-24

  Plerixafor (AMD3100) is a potent small-molecule antagonist of the CXCR4 receptor, widely used in cancer metastasis inhibition and hematopoietic stem cell mobilization research. Its well-characterized mechanism, high-affinity binding, and reproducible effects make it a cornerstone for dissecting the CXCL12/CXCR4 axis in biomedical studies.

• Tamoxifen: Selective Estrogen Receptor Modulator for Advance

  2026-04-23

  Tamoxifen’s unique versatility as a selective estrogen receptor modulator (SERM) empowers gene editing, breast cancer modeling, and kinase pathway interrogation. New evidence on caveolin-1 modulation and comparative cytotoxicity in MCF-7 cells further highlights its value for mechanistic and translational workflows.

• Cytarabine (AraC): Precision in Leukemia and Apoptosis Assay

  2026-04-23

  Cytarabine (AraC) from APExBIO sets the benchmark for DNA synthesis inhibition and apoptosis induction in leukemia research, offering robust, reproducible workflows and nuanced resistance management. This guide delivers optimized protocols, troubleshooting strategies, and novel insights from recent virology findings—empowering cell death research with data-driven precision.

• circHECTD1 Drives Glioblastoma Progression via miR-320-5p/SL

  2026-04-22

  Li et al. (2021) elucidate a novel molecular pathway in glioblastoma, demonstrating that circHECTD1 promotes tumor proliferation and migration through a miR-320-5p/SLC2A1 regulatory axis. These findings highlight circHECTD1 as a potential therapeutic target for combatting this aggressive brain cancer.

15968 records 1/1065 page Next 12345 下5页 Last page